Drug and Therapeutics Committee

Slides:



Advertisements
Similar presentations
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlikeLicense. Your use of this material constitutes acceptance of that license.
Advertisements

Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Should We Ration Health Care for Older People?
Disease State Management The Pharmacist’s Role
Introduction to Pharmacoeconomics
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Drug Utilization Review (DUR)
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Clinical Pharmacist Intervention in Cardiac Patients With Renal Impairment Elham Al-Shammari, B.Sc. Pharm. Hisham Abou-Auda, Ph. D. Meshal Al-Mutairi,
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.
Drug and Therapeutics Committee Session 7A. Identifying Problems with Medicine Use: Indicator Studies.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
1 Drug and Therapeutics Committee. Objectives  Discuss the use of aggregate data including defined daily dose in analyzing the consumption of medicines.
Paying Less By Purchasing Smarter Gerard Anderson, PhD Professor Johns Hopkins University.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Pharmacoeconomics & Drug Compliance Dr Arif Hashmi.
PHAR 310: Pharmacoeconomics
Back to Basics: Health Economics Gavin Lewis, Head of Health Economics, Roche BOPA, Brighton, 18 th October, 2009 HCMR00008 / Date of Preparation October.
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Workers’ Compensation Managed Care Pricing Considerations Prepared By: Brian Z. Brown, F.C.A.S., M.A.A.A. Lori E. Stoeberl, A.C.A.S., M.A.A.A. SESSION:
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Why to study Pharmacoeconomics? Expansion of medical knowledge Increase in the treatment options Burden on the health care professionals to provide effective.
Make Nutrition Services Count: Cost-Effectiveness Research & Outcomes Research.
Flagship Program on Health Sector Reform and Sustainable Financing.
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
The Use of Pharmacoeconomics and Pharmacoepidemiology in Your Local MTF P&T Process by Marv Shepherd, Ph.D. Jim Wilson, Ph.D. Center for Pharmacoeconomic.
Promoting high quality, cost effective drug therapy throughout the Military Health System Identification and Use of Published Health Economic Evaluations.
WHAT IS HEALTH ECONOMICS? ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ PHYSICIANS CARE ONLY ABOUT PATIENTS…… PHYSICIANS.
Capital Insight Pty Limited ABN Berry Street North Sydney NSW 2060 t f Health Economics.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Farid Abolhassani What is economic evaluation 16.
Presentation Developed for the Academy of Managed Care Pharmacy
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Pharmacy & Therapeutics Committee
HEALTH ECONOMICS BASICS
Cost Effective Studies
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Value of Pharmaceuticals in Managed Care Pharmacy
A Primer on Health Economics and Cost-Effectiveness
Pharmacy & Therapeutics Committee
NAPLEX preparation: Biostatistics
Value of Pharmaceuticals in Managed Care Pharmacy
Value of Pharmaceuticals in Managed Care Pharmacy
Pharmacy practice and the healthcare system Ola Ali Nassr
Pharmacy & Therapeutics Committee
A PILOT STUDY EXAMINING CRITERIA USED TO SELECT DRUGS FOR HOSPITAL, PROVINCIAL AND NATIONAL FORMULARIES Robertson J, Newby DA, Pillay T, Walkom EJ The.
Pharmacoeconomic Dr . Dlivan F. Aziz.
Presentation Developed for the Academy of Managed Care Pharmacy
Pharmacy & Therapeutics Committee
Value of Pharmaceuticals in Managed Care Pharmacy
Presentation transcript:

Drug and Therapeutics Committee Session 6. Evaluating the Cost of Pharmaceuticals

Introduction Adding medicines to the formulary involves careful consideration of— Efficacy Safety Quality Cost Cost factors are becoming more important Science of pharmacoeconomics is emerging

Objectives Define and understand the different types of cost analysis methods relevant to choosing medicines for the formulary Understand how to read and assess journal articles concerning an economic study Apply session materials to conduct a basic cost analysis for a medicine being requested for the formulary

Outline Introduction Key Definitions Cost-Evaluation Methods Cost-Minimization Analysis Cost-Effectiveness Analysis Evaluating Pharmacoeconomic Studies Activities Summary

Key Definitions (1) Pharmacoeconomics—the description and analysis of the cost of pharmaceutical therapy to health care systems Cost—the total resources consumed in producing a good or service Price—the amount of money required to purchase an item

Key Definitions (2) Medicine effectiveness—the effects of a medicine when used in real-life situations Medicine efficacy—the effects of a medicine under clinical trial conditions

Direct Costs of a Medicine Acquisition cost Transportation cost Supply management cost (i.e., storage facility cost) Cost of supplies and equipment to administer medicines, such as syringes and needles Personnel costs to prepare and administer such as physicians, pharmacists, and nurses Other direct costs (e.g., ADRs, hospital room charges, laboratory fees) Nonmedical cost (e.g., patient travel expenses)

Indirect Costs of a Medicine Indirect costs—examples Cost of illness to the patient Lost time from work Time required to care for somebody Intangible costs Costs associated with pain and suffering usually incorporated into utilities assigned to health states which reflect quality of life

Cost-Minimization Analysis Of two medicines with equal effectiveness, which is the least expensive? Most used cost-evaluation method Most accurate method when comparing cost between two therapeutically equivalent medicines

Cost-Minimization Analysis: Process Obtain acquisition price for each medicine and calculate the price for the course of treatment to be compared—dose per day, number of days of treatment. Calculate pharmacy, nursing, and physician costs associated with the use of each medicine. Calculate equipment cost associated with each medicine. Calculate laboratory cost associated with each medicine. Calculate cost of any other significant factor. Calculate and compare total medicine costs for each medicine.

Cost-Minimization Analysis: Example 1 Category Medicine A Medicine B Acquisition price USD* 8.00 USD15.00 Pharmacist salary 2.50 1.50 Nursing salary 2.50 2.00 Supplies 9.00 2.25 Laboratory services 4.00 1.00 Total USD 26.00 USD 21.75 *USD refers to U.S. dollar

Cost-Minimization Analysis: Example 2 Cost Categories Ampicillin Ceftriaxone Gentamicin (500 mg) (1 g) (80 mg) Acquisition price for one vial USD1.00 USD 8.00 USD 2.00 Doses per day 4 1 3 Price per day USD 4.00 USD 8.00 USD 6.00 Nursing salary at USD 0.75 per injection USD 3.00 USD 0.75 USD 2.25 Equipment: IV set at USD 1.00/set — USD 1.00 — _ Syringe/needle 0.50/set USD 2.00 — USD1.50 Laboratory tests USD 2.00 USD 2.00 USD 4.00 Total medicine costs/day USD 11.0 USD 11.75 USD 13.75 3,000 treatment-days/year 3,000 days 3,000 days 3,000 days Total medicine costs USD 33,000 USD 35,250 USD 41,250

Cost-Effectiveness Analysis (CEA) Of two medicines, A and B, with different effectiveness, what is the cost per patient cured for medicine A versus medicine B? Used to compare two or more medicines which are not therapeutically equivalent Effectiveness of therapy according to predetermined therapeutic measure, for example— Patients cured Deaths averted; years of life saved Decreased blood pressure or glycosylated hemoglobin

CEA: Steps Define objectives—which medicine regimen is preferred to achieve the desired clinical outcome (e.g., cure)? List the different options (medicines and other treatments) to achieve the desired clinical outcome. Identify and measure for each option: (1) cost and (2) clinical outcome. Calculate the incremental cost-effectiveness ratio. Perform sensitivity analyses. Adjust cost of variables and re-analyze to confirm or refute results.

Incremental Cost-Effectiveness Ratio (Net costs treatment A – Net costs treatment B) ÷ (Net effects treatment A – Net effects treatment B) = Additional cost per additional benefit

Example of CEA: Medicine Costs Cost/unit (USD)* No. of units patients Total cost (USD) Medicine A Medicine cost 40 12 100 48,000 Lab cost 20 1 2,000 Adverse event 50 2 10,000 Physician 25 5,000 Total 65,000 Medicine B 30,000 4,000 3 15,000 7,500 56,500 *USD equals U.S. dollar

Example of CEA: Benefits Effectiveness Medicine A Medicine B 25/100 patients 19/100 patients Clinical outcome: number of patients with ≥ 1% decrease in glycosylated hemoglobin over one year

Example of CEA: Incremental Cost-Effectiveness Comparison between medicines A and B for 100 patients for 1 year Medicine A Medicine B Net costs USD* 65,000 56,500 Effectiveness No. patients with ≥ 1% decrease in glycosylated hemoglobin 25 19 Incremental Cost Effectiveness Ratio = (65,000-56,500)/(25-19) = USD1,416.67 per extra patient with ≥ 1% decrease in glycosylated hemoglobin.

CEA of Two Thrombolytics in Acute Myocardial Infarction (MI) in Australia (1) Cost of treatment and mortality rates Usual care (UC) of MI: 3.5 million Australia dollars (AUD)/1,000 cases, 120 die UC+ Streptokinase (SK): AUD 3.7 million /1,000 cases, 90 die UC + tissue plasminogen activator (tPA): AUD 5.5 million /1,000 cases, 80 die Source: Australian Prescriber, 1996, 19(2): 52–54.

CEA of Two Thrombolytics in Acute MI in Australia (2)

CEA of Two Thrombolytics in Acute MI in Australia (3) 2. Difference between UC + tPA and UC of MI: Cost of treatment = AUD 5.5 – 3.5 million/1,000 cases = AUD 2.0 million/1,000 cases = AUD 2,000/case Number of deaths prevented = 120 80 = 40 deaths/1,000 cases treated Incremental cost effectiveness of tPA vs. UC = AUD 2.0 million/40 lives = AUD 50,000/life saved

CEA of Two Thrombolytics in Acute MI in Australia (4) 3. Difference between tPA and SK treatments for MI: Cost of treatment = AUD 2.0 - 0.2 million/1000 cases = AUD 1.8 million/1000 cases = AUD 1,800/case No. of deaths prevented = 90 - 80 = 10 deaths/1,000 cases treated Extra cost effectiveness of tPA over SK = AUD 1.8 million/10 lives = AUD 180,000/life saved

CEA of Two Thrombolytics in Acute MI in Australia (5)

CEA of Two Thrombolytics in Acute MI in Australia (6)

Other Controversial Cost Analyses Cost-Utility Analysis—a type of cost-effectiveness analysis in which the desired clinical outcome or benefit is measured in utilities, for example, in quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) Cost-Benefit Analysis—a comparison of the costs and benefits of an intervention by translating the health benefits into a monetary value, so that both the costs and benefits are measured in the same monetary unit

Sensitivity Testing

Discounting Used in cost evaluations to account for a future cost of a benefit from the medicine (or intervention) Method to account for effects of the medicine (or intervention) over prolonged periods of time (because of the effects of inflation) The discount rate must be tied to the economics of the country where the medicine or intervention would be provided—5% in the United States; treasury rate in the United Kingdom The discount rate is not known for sure in any pharmacoeconomic study and any arbitrary rate used will have a dramatic effect on the results of the economic study

Evaluating Pharmacoeconomic Studies (1) Important new area but difficult to evaluate Study may not be relevant to the reader’s country No “gold standard” for pharmacoeconomic studies Quality of studies varies widely Bias of many studies to support sponsor Negative outcome research seldom gets into the literature

Evaluating Pharmacoeconomic Studies (2) Key questions to ask in reading an article Is patient selection in the study similar to those in your community? Is the study applicable to your setting? Are costs of medicines fully described? Are costs of benefits or assumptions of effectiveness fully disclosed? Has a sensitivity analysis be done? Who is the sponsor?

Evaluating Pharmacoeconomic Studies (3) Key questions to ask (continued) Are all the costs associated with medicine treatment, including good and bad outcomes described (not just prices)? Costs associated with nonpharmaceutical treatments (equipment) and negative outcomes (side-effects) may be missing Has discounting been used to reflect the costs of any future benefits or consequences in present day values? Different discounting rates for medicine costs and future benefits may be used to emphasize a medicine’s cost-effectiveness ratio

Activities Activity 1—Cost Minimization Analysis of NSAIDs Activity 2—Cost-Effectiveness Analysis of Two Antimalarial Treatments

Summary Cost analysis of medicines is becoming much more important. Comprehensive analysis of medicines is necessary to fully assess the real cost of medicines and the benefits from medicine use. Pharmacoeconomic studies are very difficult to assess. Appropriate analyses should— Rely on data from clinical trials or reasonable extrapolations of these trials Use basic verifiable costing—cost minimization and cost effectiveness whenever possible